<DOC>
	<DOCNO>NCT03078257</DOCNO>
	<brief_summary>Antiplatelet treatment important coronary artery disease ( CAD ) patient .Some patient resistant antiplatelet treatment base platelet function test ( PFT ) .Currently result PFT mainly base analysis peripheral blood . instead , adverse cardiovascular event CAD patient may directly relate platelet activity coronary artery . There 's evidence system study prove PFT peripheral blood represent platelet function coronary arteries.The purpose study determine different platelet activity blood peripheral vein ( PV ) , peripheral artery ( PA ) , intracoronary artery ( IC ) CAD patient without different intervention . study divide three part : Part A : To study different platelet activity blood PV , PA , IC CAD patient dual antiplatelet therapy . Part B : To explore different platelet activity three site ST-segment elevation myocardial infarction ( STEMI ) patient administrated platelet membrane glycoprotein Ⅱb/Ⅲa ( GPⅡb/Ⅲa ) receptor antagonist ( tirofiban ) PV IC dual antiplatelet therapy . Part C : To explore different platelet activity three site STEMI patient administrate antiplatelet thrombolysin placebo PV dual antiplatelet therapy .</brief_summary>
	<brief_title>Different Platelet Activities Between Intracoronary Peripheral Blood Coronary Artery Disease Patients</brief_title>
	<detailed_description>Part A : A total 30 CAD patient recruited.All patient load dose 300 mg clopidogrel follow maintenance dose 75 mg/d least 5 day load dose 300 mg aspirin follow maintenance dose 100 mg/d least 5 day . All patient plan receive coronary arteriography ( CAG ) percutaneous coronary intervention ( PCI ) .The investigator sample blood PV , PA IC PCI.Regional difference compare blood sample PV , PA IC light aggregometry ( agonist : arachidonic acid , LTA-AA ; adenosine diphosphat , LTA-ADP ) , VerifyNow P2Y12 assay . Differences LTA VerifyNow P2Y12-assay also compare . Part B : A total 30 STEMI patient recruited.Patients randomly assign 2 groups.A group ( n=15 ) give tirofiban PV , group ( n=15 ) give IC.All patient load dose 600 mg clopidogrel 300 mg aspirin.All patient plan receive emergency PCI . Group PV : loading dose 10ug/kg tirofiban give 3 min PV , follow maintenance dose 0.15ug/kg*min 48h.Group IC : loading dose 10ug/kg tirofiban give IC , follow maintenance dose 0.15ug/kg*min 48h . Blood sample collceted PV , PA IC injection load dose tirofiban , 15min injection.Regional difference compare blood sample PV , PA IC LTA-AA ; LTA-ADP , LTA-RIS ( agonist : ristocetin ) , VerifyNow P2Y12 assay . Part C : A total 30 STEMI patient recruited.Patients randomly assign 2 groups.A group ( n=15 ) give antiplatelet thrombolysin ( frist antiplatelet drug base GP Ib receptor complete preclinical phase I clinical study , already enter phase II clinical study ) PV , group ( n=15 ) give placebo PV.All patient load dose 600 mg clopidogrel 300 mg aspirin.All patient plan receive emergency PCI.Both Groups give way , load dose 5 IU/60kg 5 min PV , follow maintenance dose 0.002 IU/kg/h 48h . Blood sample collceted PV , PA IC injection load dose antiplatelet thrombolysin placebo , 15 min injection.Regional difference compare blood sample PV , PA IC LTA-AA ; LTA-ADP , LTA-RIS VerifyNow P2Y12 assay .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Fibrinolysin</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . CAD patient plan receive coronary arteriography ( CAG ) percutaneous coronary intervention ( PCI ) . 2 . Patient age &gt; 18 year ≦75 year old ; 3 . Signed inform consent 1 . Allergy intolerance ASA , clopidogrel , tirofiban , antiplatelet thrombolysin ; 2 . Subjects high risk bleeding ( e.g . platelet count &lt; 100*109/L , know bleed diathesis , active peptic ulcer ) ; 3 . Patients plan take warfarin drug potentially could interfere antiplatelet effect . 4. severe hemodynamic instability 5. severe liver renal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Platelet Activities</keyword>
	<keyword>light aggregometry</keyword>
	<keyword>VerifyNow P2Y12-assay</keyword>
	<keyword>peripheral vein</keyword>
	<keyword>peripheral artery</keyword>
	<keyword>intracoronary artery</keyword>
	<keyword>tirofiban</keyword>
	<keyword>antiplatelet thrombolysin</keyword>
</DOC>